Thyroid Associated Orbitopathy

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Thyroid Associated Orbitopathy trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

RecruitingPhase 2

NCT04936854

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

The purpose of this study is to determine whether Sirolimus is more effective and burdened with less side effects than conventional treatment with corticosteroi…

Norway60 participantsStarted 2023-01-01

Treatment: Sirolimus 1 mg Oral Tablet, Methylprednisolone

RecruitingPhase 4

NCT06927375

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopa…

Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe…

China60 participantsStarted 2024-12-12

Treatment: Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg)

RecruitingPhase 2/3

NCT06112340

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in…

United States75 participantsStarted 2023-10-11

Treatment: linsitinib

RecruitingPhase 3

NCT03131726

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to…

Sweden80 participantsStarted 2018-01-26

Treatment: Simvastatin 40mg

All recent trials (30 shown)

CompletedPhase 3

NCT06179875

An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor…

United States143 participantsStarted 2024-01-31

Treatment: Veligrotug

CompletedPhase 3

NCT06384547

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor…

United States231 participantsStarted 2024-05-23

Treatment: VRDN-001 10 mg/kg, VRDN-001 3 mg/kg

Thyroid Associated Orbitopathy

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopa…

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

All recent trials (30 shown)

An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopa…

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

All recent trials (30 shown)

An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054)

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Changes in Orbital Macrovascular and Intraocular Microvascular Blood Flow After Orbital Decompression Surgery in Patient…

OCT Angiography Drived Alterations in Thyroid-associated Orbitopathy

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (…

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid E…

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Ja…

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized,…

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy

Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patie…

Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections

Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy